GSDME — Gasdermin E

Migration, Crosslink

📖

GSDME — Gasdermin E

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gsdme

📖 Wiki Page

gene1996 wordssynced 2026-04-02

GSDME — Gasdermin E

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GSDME — Gasdermin E</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GSDME</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GSDME — Gasdermin E</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=GSDME" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">156 edges</a></td>
</tr>
</table>

...

GSDME — Gasdermin E

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GSDME — Gasdermin E</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GSDME</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GSDME — Gasdermin E</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=GSDME" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">156 edges</a></td>
</tr>
</table>

GSDME (Gasdermin E, also historically known as DFNA5) is a gene located on chromosome 7p15.3 that encodes the gasdermin E protein — a member of the gasdermin family of pore-forming proteins. Originally identified through its role in autosomal dominant nonsensory hearing loss (DFNA5), GSDME has emerged as a critical player in programmed cell death, particularly through its involvement in pyroptosis, with significant implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and stroke[@galluzzi2018][@tan2023].

The gasdermin family shares a conserved architecture: an N-terminal effector domain that can form pores in lipid membranes, and a C-terminal inhibitory domain that suppresses activity in the full-length protein. Proteolytic cleavage releases the N-terminal fragment, which then oligomerizes to form pores in the plasma membrane, executing lytic cell death distinct from [apoptosis](/mechanisms/apoptosis)[@shi2017].

GSDME is unique among gasdermins because it can be activated by caspase-3, the canonical executioner of apoptosis, creating a bridge between apoptosis and pyroptosis that has profound implications for neuronal survival under stress conditions[@huang2023].

Gene and Protein Structure

Gene Architecture

GSDME spans approximately 32 kb and consists of 12 exons. The gene produces multiple transcript variants through alternative splicing. The canonical isoform encodes a 496-amino-acid protein with a molecular weight of approximately 55 kDa. The protein contains two major functional domains:

N-terminal domain (residues 1-275): The pore-forming region. This domain is auto-inhibited by the C-terminal domain in the full-length protein but becomes capable of oligomerizing into pores (10-20 nm diameter) upon cleavage[@xia2021].
C-terminal domain (residues 276-496): The regulatory region that maintains the protein in an inactive conformation. C-terminal domain removal is both necessary and sufficient for pore formation.

Allelic Variants and DFNA5 Hearing Loss

The DFNA5 locus was the first gene mapped for autosomal dominant nonsensory hearing loss. A pathogenic intronic G-to-A transition (c. 2325+5G>A) causes aberrant splicing, producing a truncated protein that exerts dominant-negative effects on cochlear hair cells, leading to progressive high-frequency hearing loss[@broz2020]. More than 40 families worldwide carry this mutation. The hearing loss phenotype demonstrates that GSDME is critical for hair cell survival and that its dysregulation leads to permanent sensory deficits — a mechanistic parallel to neuronal vulnerability in neurodegeneration.

Normal Biological Function

Pyroptosis Execution

Pyroptosis is a lytic, pro-inflammatory form of programmed cell death driven by gasdermin family proteins[@shi2017]. Unlike [apoptosis](/mechanisms/apoptosis), which maintains membrane integrity until engulfment by phagocytes, pyroptosis culminates in plasma membrane rupture and release of intracellular contents including IL-1beta, IL-18, and alarmins (e.g., HMGB1, ATP). This makes pyroptosis a highly immunogenic form of cell death.

Mechanism of GSDME activation:

Cleavage: GSDME is cleaved at Asp270 by activated caspase-3 (following the Asp-Gly-Leu sequence). Caspase-3 can be activated through either the intrinsic (mitochondrial) or extrinsic (death receptor) apoptotic pathway[@liu2016].

N-terminal release: The N-terminal fragment (GSDME-NT, ~30 kDa) is released from C-terminal inhibition.

Oligomerization: GSDME-NT monomers oligomerize into ring-shaped pores (typically 18 symmetric protomers, forming a pore with inner diameter of 10-15 nm).

Membrane insertion: These pores disrupt the plasma membrane, causing ion influx (Na+, Ca2+), water influx, cell swelling, and eventual lysis[@feng2022].

Relationship to GSDMD

GSDMD is the canonical pyroptosis executioner, activated by inflammatory caspases (caspase-1, -4, -5, -11) in response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)[@wang2021]. GSDME provides an alternative pyroptotic pathway triggered by apoptotic stimuli. In cells that express high levels of GSDME, apoptotic stimuli can be "re-wired" toward pyroptosis through caspase-3-mediated GSDME cleavage. This creates a functional switch:

High GSDME / low GSDMD: Caspase-3 activation leads to pyroptosis (GSDME pathway)
Low GSDME / high GSDMD: Caspase-3 activation leads to apoptosis (GSDMD not cleaved)

This switch has therapeutic implications: in neurons where GSDME is relatively highly expressed, preventing caspase-3 activation may be crucial for blocking pyroptotic neuronal death[@tan2023].

Tumor Suppression

GSDME acts as a tumor suppressor. Loss-of-function mutations are found in gastric, breast, colorectal, and other cancers. Re-expression of GSDME in GSDME-deficient tumors induces pyroptotic cell death, limiting tumor growth. This tumor-suppressive function underscores the protein's capacity for regulated, potent cell death when activated.

Autophagy Crosstalk

Autophagy provides a counterbalance to pyroptosis through at least two mechanisms: (1) selective autophagic degradation of GSDME-NT oligomers, limiting pore formation; and (2) autophagic degradation of upstream activators (e.g., inflammasome components)[@liu2021]. In neurodegeneration, autophagy impairment — a well-documented feature of [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) — would remove this protective brake, making neurons more vulnerable to pyroptotic death.

Expression in the Brain

GSDME is expressed across multiple brain regions, with particular enrichment in:

Cerebral [cortex](/brain-regions/cortex): Broad neuronal expression throughout all layers; cortical pyramidal neurons show moderate-to-high expression.
[Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 pyramidal neurons and dentate granule cells — the regions most vulnerable to [Alzheimer's disease](/diseases/alzheimers-disease) pathology.
Substantia nigra pars compacta: Dopaminergic neurons show GSDME expression; these neurons are selectively lost in [Parkinson's disease](/diseases/parkinsons-disease).
Cerebellum: Purkinje cells express GSDME; Purkinje cell loss is a feature of certain ataxias and neurodegeneration.
Spinal cord: Motor neurons express GSDME, relevant to [ALS](/diseases/amyotrophic-lateral-sclerosis) pathogenesis.
Striatum: Medium spiny neurons express GSDME.

Single-cell RNA-seq datasets (Allen Brain Atlas, Human Protein Atlas) confirm GSDME expression in neurons, astrocytes, and microglia, with elevated baseline expression in neurons relative to glia[@yi2024].

Role in Neurodegeneration

Alzheimer's Disease

GSDME-mediated pyroptosis plays a significant role in [Alzheimer's disease](/diseases/alzheimers-disease) through multiple pathways[@huang2023][@tao2024]:

Amyloid-beta induced pyroptosis: In primary neurons and mouse models, amyloid-beta oligomers activate the NLRP3 inflammasome, leading to caspase-1 activation. However, in neurons with high GSDME expression, amyloid-beta also activates caspase-3 (via mitochondrial pathway), which cleaves GSDME and triggers pyroptotic neuronal death that is distinct from and more damaging than apoptosis.

Tau pathology: In transgenic tau mice, GSDME expression increases in hippocampus and cortex. GSDME cleavage correlates with neurofibrillary tangle burden and neuronal loss.

Neuroinflammation amplification: GSDME-mediated pyroptosis releases IL-1beta and IL-18, which amplify neuroinflammation, recruit microglia, and accelerate amyloid deposition in a feed-forward loop[@tan2023].

Microglial involvement: Microglia can undergo GSDME-mediated pyroptosis in response to amyloid plaques, releasing pro-inflammatory cytokines that further damage nearby neurons.

Key evidence:

Post-mortem AD brain tissue shows significantly elevated GSDME-NT fragments compared to age-matched controls.
GSDME knockout mice show reduced neuronal loss and better cognitive performance in APP/PS1 amyloid model.
Caspase-3 inhibitors reduce GSDME cleavage and protect neurons from amyloid-beta toxicity.

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), GSDME contributes to dopaminergic neuron death through several mechanisms[@chen2024]:

Alpha-synuclein aggregation: Pre-formed alpha-synuclein fibrils trigger GSDME cleavage in dopaminergic neurons via caspase-3 activation. This is independent of the canonical NLRP3 inflammasome pathway.

Mitochondrial dysfunction: MPTP and 6-OHDA (parkinsonian neurotoxins) cause mitochondrial permeability transition, cytochrome c release, caspase-3 activation, and GSDME cleavage in vitro and in vivo.

Neuroinflammation: Activated microglia surrounding the substantia nigra undergo pyroptosis, releasing IL-1beta and TNF-alpha, which accelerate dopaminergic neuron loss.

Endoplasmic reticulum stress: ER stress in dopaminergic neurons activates caspase-12 and caspase-3, leading to GSDME cleavage.

Key evidence:

Post-mortem PD substantia nigra shows elevated GSDME and caspase-3 activation.
In MPTP mouse models, GSDME knockout provides significant neuroprotection.
α-synuclein transgenic mice show progressive GSDME activation in dopaminergic neurons.

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron death in [ALS](/diseases/amyotrophic-lateral-sclerosis) involves both apoptosis and pyroptosis. GSDME is activated by mutant SOD1, TDP-43, and FUS through caspase-3-dependent pathways:

Mutant SOD1 (G93A) transgenic mice show increased GSDME cleavage in spinal cord motor neurons before symptom onset.
TDP-43 pathology triggers GSDME-mediated pyroptosis in a caspase-3-dependent manner.
Astrocytes carrying mutant C9orf72 expansions release factors that sensitize motor neurons to GSDME pyroptosis.

Stroke and Cerebral Ischemia

Cerebral ischemia-reperfusion strongly activates GSDME-mediated pyroptosis in neurons:

Transient middle cerebral artery occlusion (tMCAO) in mice causes rapid GSDME-NT generation in the ischemic penumbra within 2-4 hours of reperfusion.
GSDME knockout reduces infarct volume by ~40% and improves functional outcomes.
Necroptosis RIPK3 can activate caspase-8, which then activates caspase-3 and GSDME, creating a crosstalk between necroptosis and pyroptosis.

Huntington's Disease

GSDME activation has been reported in Huntington's disease models, where mutant huntingtin triggers caspase-3 activation and GSDME cleavage in striatal neurons, contributing to medium spiny neuron loss.

Molecular Interactions and Pathways

Upstream Activators

Caspase-3: Primary direct activator; activated by intrinsic or extrinsic apoptotic signals.
Caspase-8: Can activate caspase-3 indirectly through the extrinsic apoptotic pathway or through RIPK3-mediated pathways.
Granzyme B: Can directly cleave GSDME at the same Asp270 site as caspase-3.

Downstream Effectors

Plasma membrane pores: 18-mer ring-shaped pores causing K+ efflux, Na+ influx, water influx.
IL-1beta and IL-18: Released through GSDME pores (not requiring gasdermin D pores).
Alarmins: HMGB1, ATP, DNA released from dying cells.

Pathway Diagram

Mermaid diagram (expand to render)

Therapeutic Targets

Caspase-3 Inhibitors

DEVD-CHO and other caspase-3 inhibitors prevent GSDME cleavage in neurons. However, systemic caspase-3 inhibition carries risks (impaired wound healing, immune dysfunction) and may simply redirect cell death from pyroptosis to necrosis[@tao2024].

Direct GSDME-NT Inhibitors

No selective GSDME-NT inhibitors exist currently, but peptides mimicking the C-terminal inhibitory domain (residues 276-496) can be delivered to neurons and are being explored as therapeutic agents[@tan2023].

Anti-inflammatory Approaches

Since inflammasome activation is an upstream trigger of GSDME pathway in some contexts, MCC950 (NLRP3 inhibitor) has shown benefit in reducing pyroptotic neuronal death.

Gene Therapy

Allele-specific silencing for the DFNA5 hearing loss variant using antisense oligonucleotides. Similar approaches could be designed to reduce GSDME expression in neurons if needed.

Research Gaps and Open Questions

Cell-type specificity: Why are certain neurons (dopaminergic, hippocampal pyramidal) more vulnerable to GSDME pyroptosis than others? Is it expression level, upstream regulatory differences, or metabolic context?

Physiological role: What is the normal physiological function of GSDME in neurons? Is baseline GSDME involved in developmental pruning or synaptic plasticity?

GSDMD vs GSDME: In neurons where both are expressed, which pyroptosis pathway dominates? Does GSDMD contribute to neuronal pyroptosis independently?

Therapeutic window: At what disease stage does GSDME inhibition provide maximal benefit? Pre-symptomatic or after pathology is established?

Biomarkers: Are there blood or CSF markers of GSDME activation (e.g., GSDME-NT fragments, IL-18) that could serve as diagnostic or prognostic biomarkers?

References

[Shi J, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature (2017)](https://pubmed.ncbi.nlm.nih.gov/28912641/)

[Liu X, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature (2016)](https://pubmed.ncbi.nlm.nih.gov/27538955/)

[Wang Y, et al. Pyroptosis and Alzheimer's disease: gasdermin D in neurodegeneration. J Neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34763688/)

[Galluzzi L, et al. Molecular mechanisms of cell death: Nomenclature Committee on Cell Death 2018. Cell Death Differ (2018)](https://pubmed.ncbi.nlm.nih.gov/29362479/)

[Tang Z, et al. Pyroptosis in neurodegenerative diseases. Front Cell Neurosci (2020)](https://pubmed.ncbi.nlm.nih.gov/33100985/)

[Xia X, et al. What role does GSDME play in chemotherapy-induced tissue injury? Trends Cell Biol (2021)](https://pubmed.ncbi.nlm.nih.gov/33223002/)

[Feng Y, et al. GSDME-mediated pyroptosis in neurodegeneration. Mol Neurodegener (2022)](https://pubmed.ncbi.nlm.nih.gov/36104647/)

[Tan MS, et al. Gasdermin E in neurological diseases. Prog Neurobiol (2023)](https://pubmed.ncbi.nlm.nih.gov/37201969/)

[Huang R, et al. Inflammasome-dependent neuronal pyroptosis in Alzheimer's disease. J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37648982/)

[Tao P, et al. Targeting pyroptosis for Alzheimer's disease therapy. Ageing Res Rev (2024)](https://pubmed.ncbi.nlm.nih.gov/38367891/)

[Chen L, et al. Pyroptosis in Parkinson's disease: mechanisms and therapeutic strategies. Front Mol Neurosci (2024)](https://pubmed.ncbi.nlm.nih.gov/38486342/)

[Yi Q, et al. The emerging role of GSDME in neurological disorders. Mol Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38710923/)

[Liu Y, et al. Crosstalk between pyroptosis and autophagy in neurodegenerative diseases. Cell Mol Neurobiol (2021)](https://pubmed.ncbi.nlm.nih.gov/34021782/)

Pathway Diagram

The following diagram shows the key molecular relationships involving GSDME — Gasdermin E discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GSDME

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gsdme
kg_node_id	GSDME
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0d061e67603c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gsdme'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GSDME — Gasdermin E

GSDME — Gasdermin E

Overview

GSDME — Gasdermin E

Overview

Gene and Protein Structure

Gene Architecture

Allelic Variants and DFNA5 Hearing Loss

Normal Biological Function

Pyroptosis Execution

Relationship to GSDMD

Tumor Suppression

Autophagy Crosstalk

Expression in the Brain

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Stroke and Cerebral Ischemia

Huntington's Disease

Molecular Interactions and Pathways

Upstream Activators

Downstream Effectors

Pathway Diagram

Therapeutic Targets

Caspase-3 Inhibitors

Direct GSDME-NT Inhibitors

Anti-inflammatory Approaches

Gene Therapy

Research Gaps and Open Questions

See Also

References

Pathway Diagram

💬 Discussion